Baseline characteristics
| Characteristics . | Total (N = 242) . | CL+ (n = 113) . | CL– (n = 129) . | P value . |
|---|---|---|---|---|
| Age in y, median (range) | 65 (23-91) | 66 (23-91) | 65 (32-91) | .52 |
| Sex, n (%) | .20 | |||
| Male | 126 (52) | 64 (57) | 62 (48) | |
| Female | 116 (48) | 49 (43) | 67 (52) | |
| MZL subtype, n (%) | <.0001 | |||
| NMZL | 88 (36) | 31 (27) | 57 (44) | |
| SMZL | 83 (34) | 58 (51) | 25 (19) | |
| EMZL | 71∗ (29) | 24 (21) | 47 (36) | |
| ECOG PS, n (%) | .16 | |||
| 0-1 | 190 (93) | 91 (89) | 99 (96) | |
| ≥2 | 15 (7) | 11 (11) | 4 (4) | |
| Stage, n (%) | <.0001 | |||
| III | 39 (16) | 0 (0) | 39 (30) | |
| IV | 203 (84) | 113 (100) | 90 (70) | |
| B symptoms, n (%) | 49 (21) | 19 (18) | 30 (24) | .26 |
| BM involvement, n (%) | 137 (81) | 91 (91) | 46 (67) | <.0001 |
| Albumin <ULN (%) | 34 (15) | 19 (19) | 15 (13) | .26 |
| LDH >ULN, n (%) | 78 (37) | 47 (47) | 31 (28) | <.01 |
| B2M elevated, n (%) | 53 (78) | 33 (89) | 20 (65) | .02 |
| Monoclonal protein, n (%) | 61 (39) | 29 (37) | 32 (41) | .62 |
| Treatment modality, n (%) | .55 | |||
| R monotherapy | 115 (48) | 59 (52) | 56 (43) | |
| Immunochemotherapy | 98 (41) | 41 (36) | 57 (44) | |
| Local | 21 (9) | 9 (8) | 12 (9) | |
| Others | 13 (3) | 4 (3) | 9 (4) |
| Characteristics . | Total (N = 242) . | CL+ (n = 113) . | CL– (n = 129) . | P value . |
|---|---|---|---|---|
| Age in y, median (range) | 65 (23-91) | 66 (23-91) | 65 (32-91) | .52 |
| Sex, n (%) | .20 | |||
| Male | 126 (52) | 64 (57) | 62 (48) | |
| Female | 116 (48) | 49 (43) | 67 (52) | |
| MZL subtype, n (%) | <.0001 | |||
| NMZL | 88 (36) | 31 (27) | 57 (44) | |
| SMZL | 83 (34) | 58 (51) | 25 (19) | |
| EMZL | 71∗ (29) | 24 (21) | 47 (36) | |
| ECOG PS, n (%) | .16 | |||
| 0-1 | 190 (93) | 91 (89) | 99 (96) | |
| ≥2 | 15 (7) | 11 (11) | 4 (4) | |
| Stage, n (%) | <.0001 | |||
| III | 39 (16) | 0 (0) | 39 (30) | |
| IV | 203 (84) | 113 (100) | 90 (70) | |
| B symptoms, n (%) | 49 (21) | 19 (18) | 30 (24) | .26 |
| BM involvement, n (%) | 137 (81) | 91 (91) | 46 (67) | <.0001 |
| Albumin <ULN (%) | 34 (15) | 19 (19) | 15 (13) | .26 |
| LDH >ULN, n (%) | 78 (37) | 47 (47) | 31 (28) | <.01 |
| B2M elevated, n (%) | 53 (78) | 33 (89) | 20 (65) | .02 |
| Monoclonal protein, n (%) | 61 (39) | 29 (37) | 32 (41) | .62 |
| Treatment modality, n (%) | .55 | |||
| R monotherapy | 115 (48) | 59 (52) | 56 (43) | |
| Immunochemotherapy | 98 (41) | 41 (36) | 57 (44) | |
| Local | 21 (9) | 9 (8) | 12 (9) | |
| Others | 13 (3) | 4 (3) | 9 (4) |
B2M, beta 2 microglobulin; BM, bone marrow; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; R, rituximab; ULN, upper limit of normal.
Boldface values indicate statistical significance.
EMZL breakdown per primary site: lung = 15, gastro-intestinal = 13, oculo-adnexal = 13, salivary = 2, BM only = 2, breast = 2, >1 site = 14.